Michael Diamond
Overview
Explore the profile of Michael Diamond including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
320
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pinski A, Gan T, Lin S, Droit L, Diamond M, Barouch D, et al.
J Virol
. 2024 Mar;
98(4):e0004324.
PMID: 38497664
Human adenoviruses (HAdVs) are causative agents of morbidity and mortality throughout the world. These double-stranded DNA viruses are phylogenetically classified into seven different species (A-G). HAdV-G52, originally isolated in 2008...
2.
Addetia A, Piccoli L, Case J, Park Y, Beltramello M, Guarino B, et al.
bioRxiv
. 2023 Jan;
PMID: 36711984
Currently circulating SARS-CoV-2 variants acquired convergent mutations at receptor-binding domain (RBD) hot spots. Their impact on viral infection, transmission, and efficacy of vaccines and therapeutics remains poorly understood. Here, we...
3.
Ali D, Diamond M, Williams S, Patel J, Dardik M, Frank R
Urol Case Rep
. 2022 Mar;
43:102049.
PMID: 35300352
Cystadenoma of the tunica of the adult male testis has rarely been reported in the literature. We report a case of an adult serous cystadenoma along with the radiological and...
4.
Kawaoka Y, Uraki R, Kiso M, Iida S, Imai M, Takashita E, et al.
Res Sq
. 2022 Mar;
PMID: 35233565
The recent emergence of SARS-CoV-2 Omicron variants possessing large numbers of mutations has raised concerns of decreased effectiveness of current vaccines, therapeutic monoclonal antibodies, and antiviral drugs for COVID-19 against...
5.
Christensen M, Gettelman A, cermak J, Dagan G, Diamond M, Douglas A, et al.
Atmos Chem Phys
. 2022 Feb;
22(1):641-674.
PMID: 35136405
Aerosol-cloud interactions (ACIs) are considered to be the most uncertain driver of present-day radiative forcing due to human activities. The nonlinearity of cloud-state changes to aerosol perturbations make it challenging...
6.
Diamond M, Halfmann P, Maemura T, Iwatsuki-Horimoto K, Iida S, Kiso M, et al.
Res Sq
. 2022 Jan;
PMID: 34981044
Despite the development and deployment of antibody and vaccine countermeasures, rapidly-spreading SARS-CoV-2 variants with mutations at key antigenic sites in the spike protein jeopardize their efficacy. The recent emergence of...
7.
VanBlargan L, Errico J, Halfmann P, Zost S, Crowe J, Purcell L, et al.
Res Sq
. 2022 Jan;
PMID: 34981042
The emergence of the highly-transmissible B.1.1.529 Omicron variant of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody countermeasure efficacy because of the number of mutations in the...
8.
Diamond M
J Interferon Cytokine Res
. 2021 Jun;
41(6):200-202.
PMID: 34161171
No abstract available.
9.
Diamond M, Chen R, Winkler E, Case J, Aziati I, Bricker T, et al.
Res Sq
. 2021 May;
PMID: 34013259
Rapidly-emerging variants jeopardize antibody-based countermeasures against SARS-CoV-2. While recent cell culture experiments have demonstrated loss of potency of several anti-spike neutralizing antibodies against SARS-CoV-2 variant strains1-3, the in vivo significance...
10.
VanBlargan L, Adams L, Liu Z, Chen R, Gilchuk P, Raju S, et al.
bioRxiv
. 2021 Apr;
PMID: 33907753
With the emergence of SARS-CoV-2 variants with increased transmissibility and potential resistance, antibodies and vaccines with broadly inhibitory activity are needed. Here we developed a panel of neutralizing anti-SARS-CoV-2 mAbs...